Pharmacokinetics and Safety of Valaciclovir in Children with Epstein-Barr Virus Illness

ISSN： 1174-5886

Source： Drugs in R&D, Vol.3, Iss.6, 2002-01, pp. : 365-373

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lytic replication of Epstein–Barr virus

By Lu Chih-Chung Chen Mei-Ru

Future Virology, Vol. 1, Iss. 4, 2006-07 ,pp. : 435-446

Future Medicine

Access to resources Recommend Favorite

Epstein-Barr virus and multiple sclerosis: association or causation?

By Pakpoor Julia Giovannoni Gavin Ramagopalan Sreeram V

Expert Review of Neurotherapeutics, Vol. 13, Iss. 3, 2013-03 ,pp. : 287-297

Informa Healthcare

Access to resources Recommend Favorite

Epstein–Barr virus: novel patented therapeutics

By De Paoli Paolo

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 6, 2010-06 ,pp. : 807-818

Informa Healthcare

Access to resources Recommend Favorite

Ciclosporin: Epstein-Barr virus-associated lymphoproliferative disorder: case report

Reactions Weekly, Vol. 1, Iss. 1047, 2005-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Antineoplastics: Epstein-Barr virus lymphoproliferative disease in a child: case report

Reactions Weekly, Vol. 1, Iss. 1193, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite